Alkeus Pharmaceuticals Receives FDA Rare Pediatric Disease and Fast Track Designations for Gildeuretinol as a Treatment for Stargardt Disease
18 nov. 2024 09h16 HE
|
Alkeus Pharmaceuticals
Alkeus Pharmaceuticals, Inc. receives FDA Rare Pediatric Disease and Fast Track designations for gildeuretinol as a treatment for Stargardt Disease
Topline Results from Alkeus Pharmaceuticals’ Study of Oral Gildeuretinol Demonstrate Significant Trend in Slowing GA Progression and Visual Function Improvement
23 oct. 2024 09h00 HE
|
Alkeus Pharmaceuticals
Alkeus Pharmaceuticals, Inc., today announced that results from its study of gildeuretinol in geographic atrophy were presented at AAO 2024.
AAVantgarde announces 3 oral presentations at ESGCT 2024 annual meeting
08 oct. 2024 02h00 HE
|
AAVantgarde Bio
MILAN, Oct. 08, 2024 (GLOBE NEWSWIRE) -- AAVantgarde Bio (AAVantgarde), a clinical-stage, Italian-based international biotechnology company with two proprietary Adeno-Associated Viral (AAV) vector...
Alkeus Pharmaceuticals Announces Presentation of a TEASE-3 Study Update Showing Progression Stalled in Early-Stage Stargardt Disease Patients Treated with Gildeuretinol
18 juil. 2024 10h20 HE
|
Alkeus Pharmaceuticals
Alkeus Pharmaceuticals announces presentation of a TEASE-3 study update showing progression stalled in early-stage Stargardt disease
Alkeus Pharmaceuticals Announces Presentation of Positive Gildeuretinol Data in Early-Stage Stargardt Patients During the ARVO 2024 Annual Meeting May 5-9
01 mai 2024 09h00 HE
|
Alkeus Pharmaceuticals
Alkeus Pharmaceuticals Announces Presentation of Positive Gildeuretinol Data in Early-Stage Stargardt Patients During the ARVO 2024 Annual Meeting May 5-9
AAVantgarde announces updated NHP data from its Stargardt disease program in a poster presentation at the ARVO 2024 annual meeting
24 avr. 2024 02h00 HE
|
AAVantgarde Bio
AAVantgarde announces updated NHP data from its Stargardt disease program in a poster presentation at the ARVO 2024 annual meeting
AAVantgarde presents positive preclinical data in large animal models from its Stargardt disease program in an oral presentation at the ASGCT 2024 annual meeting
23 avr. 2024 02h00 HE
|
AAVantgarde Bio
AAVantgarde presents positive preclinical data in large animal models from its Stargardt disease program in an oral presentation at ASGCT 2024
Alkeus Pharmaceuticals Presents Positive Interim Data Showing Gildeuretinol Halted Stargardt Disease Progression
10 janv. 2024 06h00 HE
|
Alkeus Pharmaceuticals
All three patients treated for two years or more have remained free of symptoms and disease progression while taking gildeuretinol.TEASE-3 is the first clinical trial in early-stage Stargardt disease,...
AAVantgarde Closes €61 Million Series A Financing to Advance Two Therapeutic Programs into the Clinic
06 juin 2023 08h00 HE
|
AAVantgarde Bio
- Financing led by Atlas Venture and Forbion - Company created, incubated and seed financed by Sofinnova Partners MILAN, Italy, June 06, 2023 (GLOBE NEWSWIRE) -- AAVantgarde Bio (AAVantgarde), a...
Alkeus Announces $150 Million Series B Financing, Supporting Rapid Registration Path for gildeuretinol (ALK-001) in the Treatment of Stargardt Disease
05 juin 2023 06h00 HE
|
Alkeus Pharmaceuticals
CAMBRIDGE, Mass., June 05, 2023 (GLOBE NEWSWIRE) -- Alkeus Pharmaceuticals announced today that it has raised a $150 million Series B financing to support the registration and launch of...